New Search

If you are not happy with the results below please do another search

Search
Generic filters

50 search results for:

12

Merck Pauses Enrollment for Two Phase 3 Clinical Trials of Investigational, Once-Monthly, Oral Islatravir for Pre-Exposure Prophylaxis of HIV-1 infection

Merck announced a pause in enrollment for the IMPOWER 22 (MK-8591-022) and IMPOWER 24 (MK-8591-024) Phase 3 clinical studies evaluating investigational, once-monthly, oral islatravir (ISL) – a nucleoside reverse transcriptase translocation inhibitor – for pre-exposure prophylaxis (PrEP) in people at high risk of HIV-1 infection.